Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.

Henry RR, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, Pratley RE

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Nov 2011Cited by 42 (Europe PMC)

PMID22193143DOI10.4158/ep.17.6.906PepBankPUB-22193143

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes, liraglutide produced the greatest A1C reductions across all baseline A1C categories, 0.7% to 1.8%, compared with other antihyperglycemic treatments.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered A1C the most of the drugs compared, at every starting A1C level.
Peptide
Liraglutide
Outcome
DecreaseA1C reduction across baseline A1C categories
Study
n: not reported in source
Comparator
Sitagliptin, glimepiride, rosiglitazone, exenatide, insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg daily · 26 weeksAs given in this study (human).
Measurements
A1C reduction
0.7 to 1.8%
liraglutide, baseline categories
Source sentences
Summary
After 26 weeks of treatment, liraglutide produced the greatest reductions in A1C values across all baseline categories, ranging from 0.7% to 1.8% (baseline A1C categories ≤7.5% to >9.0%, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
Pooled patient data from 7 phase 3, multinational, randomized controlled trials in patients with type 2 diabetes were stratified by baseline A1C values into 5 categories: ≤7.5%, >7.5% to 8.0%, >8.0% to 8.5%, >8.5% to 9.0%, and y9.0%.
Summary · context
The changes in A1C from baseline to week 26 of treatment and patient proportions reaching A1C targets of <7.0% and ≤6.5% were compared between liraglutide (1.8 mg daily) and sitagliptin, glimepiride, rosiglit-azone, exenatide, and insulin glargine across all baseline A1C categories.
Report a problemFND-2219314301
02HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes, generally larger percentages reached an A1C of 6.5% or lower with liraglutide than with other treatments across baseline A1C categories.
In plain wordsIn adults with type 2 diabetes, more people reached an A1C of 6.5% or lower with liraglutide than with other drugs.
Peptide
Liraglutide
Outcome
IncreaseReaching A1C target of 6.5% or lower
Study
n: not reported in source
Comparator
Other treatments
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg daily · 26 weeksAs given in this study (human).
Measurements
Proportion at target
10 to 62%
liraglutide, baseline categories
Source sentences
Summary
Generally, larger percentages of patients achieved the A1C target of ≤6.5% with liraglutide therapy across all baseline categories (from 62% of patients with A1C values ≤7.5% to 10% of patients with A1C values >9.0%) in comparison with other treatments (ranging from 49% to 0% of patients, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Pooled patient data from 7 phase 3, multinational, randomized controlled trials in patients with type 2 diabetes were stratified by baseline A1C values into 5 categories: ≤7.5%, >7.5% to 8.0%, >8.0% to 8.5%, >8.5% to 9.0%, and y9.0%.
Summary · context
The changes in A1C from baseline to week 26 of treatment and patient proportions reaching A1C targets of <7.0% and ≤6.5% were compared between liraglutide (1.8 mg daily) and sitagliptin, glimepiride, rosiglit-azone, exenatide, and insulin glargine across all baseline A1C categories.
Report a problemFND-2219314302
03HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes, greater proportions reached an A1C below 7.0% with liraglutide than with comparators, across all baseline categories.
In plain wordsIn adults with type 2 diabetes, more people reached an A1C below 7.0% with liraglutide than with the comparison drugs.
Peptide
Liraglutide
Outcome
IncreaseReaching A1C target below 7.0%
Study
n: not reported in source
Comparator
Comparators
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg daily · 26 weeksAs given in this study (human).
Measurements
Proportion at target
25 to 83%
liraglutide, baseline categories
Source sentences
Summary
Similarly, greater proportions of patients also reached the A1C target of 9.0%) versus comparators (from 74% to 5% of patients, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Pooled patient data from 7 phase 3, multinational, randomized controlled trials in patients with type 2 diabetes were stratified by baseline A1C values into 5 categories: ≤7.5%, >7.5% to 8.0%, >8.0% to 8.5%, >8.5% to 9.0%, and y9.0%.
Summary · context
The changes in A1C from baseline to week 26 of treatment and patient proportions reaching A1C targets of <7.0% and ≤6.5% were compared between liraglutide (1.8 mg daily) and sitagliptin, glimepiride, rosiglit-azone, exenatide, and insulin glargine across all baseline A1C categories.
Report a problemFND-2219314303

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

04HumanNot a test of Liraglutide aloneSystematic reviewOther
In patients with type 2 diabetes, A1C reductions irrespective of treatment were generally greater in groups with higher baseline A1C.
In plain wordsIn adults with type 2 diabetes, whatever the drug, people with higher starting A1C generally saw bigger falls.
Peptide
Liraglutide
Outcome
Not applicableEffect of baseline A1C on A1C reduction (all treatments)
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Irrespective of treatment, reductions in A1C levels were generally greater in groups with higher baseline A1C values.
2 context sentences(design, population, supporting numbers)
Summary · context
Pooled patient data from 7 phase 3, multinational, randomized controlled trials in patients with type 2 diabetes were stratified by baseline A1C values into 5 categories: ≤7.5%, >7.5% to 8.0%, >8.0% to 8.5%, >8.5% to 9.0%, and y9.0%.
Summary · context
The changes in A1C from baseline to week 26 of treatment and patient proportions reaching A1C targets of <7.0% and ≤6.5% were compared between liraglutide (1.8 mg daily) and sitagliptin, glimepiride, rosiglit-azone, exenatide, and insulin glargine across all baseline A1C categories.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2219314304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials7

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

7 trials · 6 completed · 1 stopped early · 4 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00700817